Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 7/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452529 | 0.88 | LMNA (0.59) | TAS2R14MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3837668 | 0.85 | CNR2 (0.71) | TAS2R14MEN1KMT2ACNR2CNR1 | |
| SCHEMBL1279080 | 0.84 | TAS2R14 (0.77) | TAS2R14CNR2CNR1CXCR3 | |
| SCHEMBL5450808 | 0.82 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4709007 | 0.82 | TAS2R14 (0.65) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16568638 | 0.81 | L3MBTL1 (0.64) | TAS2R14MEN1KMT2ACNR2CNR1 | |
| SCHEMBL6609506 | 0.80 | HTT (0.66) | TAS2R14MEN1KMT2ACNR2LMNA | |
| SCHEMBL5466187 | 0.79 | CA9 (0.67) | TAS2R14MAPTPOLB | |
| SCHEMBL6607386 | 0.79 | TAS2R14 (0.50) | TAS2R14MEN1KMT2AMAPTPOLB | |
| SCHEMBL16058260 | 0.78 | CNR2 (0.58) | TAS2R14MEN1KMT2ACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| CN-1608061-A | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | CN | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | TAS2R14 315/4885MEN1 385/4885KMT2A 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.